

To view this email as a web page, go [here](#).

Message below is a paid advertisement. Content is provided by the sponsor.

DermatologyTimes

Clinical Insights That Expand Expertise and Advance Practice

Enstilar[®]

(calcipotriene and betamethasone dipropionate) Foam 0.005%/0.064%

has an expanded indication!

Click anywhere for all the details.



The LEO Pharma logo, Leo Pharma, and Enstilar are registered trademarks of LEO Pharma A/S. ©2019 LEO Pharma Inc. All rights reserved. August 2019 MAT-27571



NDC 50222-002-60

Enstilar[®]

(calcipotriene and betamethasone dipropionate) Foam, 0.005%/0.064%

Shake before Use

For Topical Use Only

Not for ophthalmic, oral or intravaginal use

You received this e-mail because you are a customer of Dermatology Times, a MJH Life Sciences publication. You are on the mailing list as stefanie.nathanson@ubm.com

To ensure delivery to your Inbox, please add us to your address book.

From time to time, we will inform customers of latest offers and new products from relevant business partners. If you do not wish to receive this type of information, [click here](#).

If you would like to contact us by phone, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-7223. Outside the U.S., please phone 1-218-740-6895.

Dermatology Times, a MJH Life Sciences publication
325 W 1st St Ste 300,
Duluth, MN 55802-2065 USA.
[Privacy Policy](#)